Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Company Overview

Lisata Therapeutics, Inc. (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies. To advance its programs, the company collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe.

Headquartered in the United States, Lisata Therapeutics is governed by a leadership team with experience in biotechnology research, clinical operations and regulatory affairs. The company’s board and scientific advisors bring expertise in immunology, drug development and commercial strategy to support its mission of addressing unmet medical needs.

Key Stats

• Today's Range: $2.28 to $2.33
• 50-Day Range: $2.11 to $2.96
• 52-Week Range: $1.87 to $4.20
• Volume: 4,155 shs
• Average Volume: 30,713 shs
• Market Capitalization: $20.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.50
• Consensus Rating: Buy

Lisata Therapeutics Stock Analysis - MarketRank™

Lisata Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 373rd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Lisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Lisata Therapeutics has a consensus price target of $23.50, representing about 895.8% upside from its current price of $2.36.

Amount of Analyst Coverage

Lisata Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lisata Therapeutics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lisata Therapeutics is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lisata Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently decreased by 27.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lisata Therapeutics does not currently pay a dividend.

Dividend Growth

Lisata Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.17% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently decreased by 27.04%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Lisata Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of Lisata Therapeutics is held by insiders.

Percentage Held by Institutions

Only 8.94% of the stock of Lisata Therapeutics is held by institutions.

LSTA Stock Analysis - Frequently Asked Questions

How have LSTA shares performed this year?

Lisata Therapeutics' stock was trading at $2.98 at the start of the year. Since then, LSTA stock has decreased by 20.8% and is now trading at $2.36.

How were Lisata Therapeutics' earnings last quarter?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced its earnings results on Thursday, August, 7th. The company reported ($0.54) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.11. The firm earned $0.07 million during the quarter.
Read the conference call transcript.

Who are Lisata Therapeutics' major shareholders?

Top institutional shareholders of Lisata Therapeutics include BML Capital Management LLC (2.40%) and Cerity Partners LLC (0.14%).

How do I buy shares of Lisata Therapeutics?

Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lisata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LSTA
• CIK: 320017
• Web: www.caladrius.com
• Phone: (908) 842-0100
• Fax: 646-514-7787
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lisata Therapeutics: $23.50
• High Price Target: $32.00
• Low Price Target: $15.00
• Potential Upside/Downside: +895.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.99 million
• Net Margins: N/A
• Pretax Margin: -1,858.41%
• Return on Equity: -69.68%
• Return on Assets: -59.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.77
• Quick Ratio: 5.77

Sales & Book Value

• Annual Sales: $1.07 million
• Price / Sales: 19.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.49 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 8,756,000
• Free Float: 7,915,000
• Market Cap: $20.66 million
• Optionable: Not Optionable
• Beta: 1.01